Improvising 5-HT7R homology model for design of high affinity ligands: model validation with docking, embrace minimization, MM-GBSA, and molecular dynamic simulations

The subtype, 5-HT7R has been implicated in neurological disorders and presents itself as a promising target for antidepressant drugs. Design of targeted selective ligands, require a sound knowledge of 3D-receptor structure. In absence of receptor structure, structure-based design of targeted ligands relies on generation of 5-HT7R homology model. In this study, the impact of template choice, alignment, and model building methods on the homology model of 5-HT7R is addressed. The compactness and model quality due to the presence of cholesterol (lipidic receptor) have also been observed. The results suggest good stereochemical quality of the final model. Ramachandran Plot Analysis indicated more than 97.5% amino acid residues in the favorable region. The overall quality factor was 91.8% using ERRAT. The Z-score for backbone confirmation and packing quality were −1.248 and −1.427, respectively, using WHATCHECK. The RMS Z-score for side chain planarity was .711. Other validation results for the final model include binding site analysis in which Asp162, Val163, Phe343, Phe344, Arg350, Arg367, and Leu370 conserved residues were found in the active site, correlation coefficient of .82 in ligand-based screening and .85 in embrace minimization. Further, the model showed good correlation for agonist and antagonist in docking ( ≈ .76, ≈ .82), embrace minimization ( ≈ .73, ≈ .72), and MM-GBSA ( ≈ .69, ≈ .75) studies. The model was subjected to Molecular Dynamics (MD) simulation of 20 ns both in ligand-free and ligand-bound receptor (agonist and antagonist) system in order to assess its stability.

[1]  J. Hagan,et al.  5-HT7 receptors. , 2004, Current drug targets. CNS and neurological disorders.

[2]  E. Lacivita,et al.  Selective 5-HT7 receptor agonists LP 44 and LP 211 elicit an analgesic effect on formalin-induced orofacial pain in mice , 2016, Journal of applied oral science : revista FOB.

[3]  J. Åqvist,et al.  Phe369(7.38) at human 5‐HT7 receptors confers interspecies selectivity to antagonists and partial agonists , 2010, British journal of pharmacology.

[4]  Marco Biasini,et al.  SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information , 2014, Nucleic Acids Res..

[5]  Andrzej J. Bojarski,et al.  New Strategy for Receptor-Based Pharmacophore Query Construction: A Case Study for 5-HT7 Receptor Ligands , 2013, J. Chem. Inf. Model..

[6]  R. Jakus,et al.  Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy , 2004, Neuroscience Letters.

[7]  N. Vaidehi,et al.  Conserved Mechanism of Conformational Stability and Dynamics in G-Protein-Coupled Receptors. , 2016, Journal of chemical theory and computation.

[8]  A. Giuliani,et al.  A computational approach identifies two regions of Hepatitis C Virus E1 protein as interacting domains involved in viral fusion process , 2009, BMC Structural Biology.

[9]  Mateusz Nowak,et al.  Receptor-based pharmacophores for serotonin 5-HT7R antagonists-implications to selectivity. , 2006, Journal of medicinal chemistry.

[10]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[11]  M. Leopoldo,et al.  The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat , 2008, Behavioural Brain Research.

[12]  David E. Gloriam,et al.  Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. , 2006, Genomics.

[13]  R Sowdhamini,et al.  Molecular modelling of human 5-hydroxytryptamine receptor (5-HT2A) and virtual screening studies towards the identification of agonist and antagonist molecules , 2016, Journal of biomolecular structure & dynamics.

[14]  J. Terrón,et al.  Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine? , 2002, European journal of pharmacology.

[15]  L. Pardo,et al.  Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives. , 2003, Journal of medicinal chemistry.

[16]  Zhijun Li,et al.  Improving homology modeling of G-protein coupled receptors through multiple-template derived conserved inter-residue interactions , 2014, Journal of Computer-Aided Molecular Design.

[17]  A. Sleight,et al.  Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. , 1995, Molecular pharmacology.

[18]  Torsten Schwede,et al.  Modelling three-dimensional protein structures for applications in drug design. , 2014, Drug discovery today.

[19]  J. Hagan,et al.  Characterization of SB‐269970‐A, a selective 5‐HT7 receptor antagonist , 2000, British journal of pharmacology.

[20]  G. Haegeman,et al.  Role of the 5-HT7 Receptor in the Central Nervous System: from Current Status to Future Perspectives , 2011, Molecular Neurobiology.

[21]  Arne Elofsson,et al.  Using multiple templates to improve quality of homology models in automated homology modeling , 2008, Protein science : a publication of the Protein Society.

[22]  Murugesan Ramachandran,et al.  Multiple templates-based homology modeling enhances structure quality of AT1 receptor: validation by molecular dynamics and antagonist docking , 2011, Journal of molecular modeling.

[23]  Afshin Fassihi,et al.  Exploring a Model of a Chemokine Receptor/Ligand Complex in an Explicit Membrane Environment by Molecular Dynamics Simulation: The Human CCR1 Receptor , 2011, J. Chem. Inf. Model..

[24]  R. Eglen,et al.  Characterization of putative 5‐ht7 receptors mediating direct relaxation in Cynomolgus monkey isolated jugular vein , 1996, British journal of pharmacology.

[25]  Durba Sengupta,et al.  Molecular modeling of the human serotonin(1A) receptor: role of membrane cholesterol in ligand binding of the receptor. , 2011, Molecular bioSystems.

[26]  M. Kołaczkowski,et al.  Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia. , 2014, Journal of medicinal chemistry.

[27]  K. Krobert,et al.  Identification of essential residues for binding and activation in the human 5-HT7(a) serotonin receptor by molecular modeling and site-directed mutagenesis , 2015, Front. Behav. Neurosci..

[28]  Andrzej J. Bojarski,et al.  Impact of Template Choice on Homology Model Efficiency in Virtual Screening , 2014, J. Chem. Inf. Model..

[29]  Tom Halgren,et al.  New Method for Fast and Accurate Binding‐site Identification and Analysis , 2007, Chemical biology & drug design.

[30]  G. N. Ramachandran,et al.  Stereochemistry of polypeptide chain configurations. , 1963, Journal of molecular biology.

[31]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[32]  Rafał Kurczab,et al.  Towards novel 5-HT7versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: design, synthesis, and antidepressant properties. Part II. , 2015, European journal of medicinal chemistry.

[33]  A. Mishra,et al.  Synthesis, docking and preliminary in vivo evaluation of serotonin dithiocarbamate as novel SPECT neuroimaging agent , 2013 .

[34]  V. Vyas,et al.  Homology Modeling a Fast Tool for Drug Discovery: Current Perspectives , 2012, Indian journal of pharmaceutical sciences.

[35]  J. Lavandera,et al.  First pharmacophoric hypothesis for 5-HT7 antagonism. , 2000, Bioorganic & medicinal chemistry letters.

[36]  R. E. Salmas,et al.  Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations , 2015, Scientific Reports.

[37]  Takatsugu Hirokawa,et al.  Extended Template-Based Modeling and Evaluation Method Using Consensus of Binding Mode of GPCRs for Virtual Screening , 2014, J. Chem. Inf. Model..

[38]  M. Buhot Serotonin receptors in cognitive behaviors , 1997, Current Opinion in Neurobiology.

[39]  Jessica Sallander,et al.  Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. , 2009, Journal of medicinal chemistry.

[40]  A. Meneses Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task , 2004, Behavioural Brain Research.

[41]  Anne W. Schmidt,et al.  Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides. , 2004, Journal of medicinal chemistry.

[42]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[43]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.